EUCTR2017-003399-30-AT
Active, not recruiting
Phase 1
A Prospective, Randomized, Double-Blind Comparison of LY900014 and Fiasp®, Both in Combination with Basal Insulin in Adults with Type 1 Diabetes, PRONTO-Compare - PRONTO-Compare
DrugsFiasp®
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Eli Lilly and Company
- Enrollment
- 632
- Status
- Active, not recruiting
- Last Updated
- 7 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •You are diagnosed with type 1 diabetes and have been using insulin continuously for at least 12 months
- •You are 18 years of age or older
- •You are already being treated with insulin allowed for study participation.
- •Your blood glucose levels are within allowed limits for study participation
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1\.2 Adults (18\-64 years) yes
- •F.1\.2\.1 Number of subjects for this age range 581
- •F.1\.3 Elderly (\>\=65 years) yes
- •F.1\.3\.1 Number of subjects for this age range 51
Exclusion Criteria
- •You have had more than 1 emergency treatment for very low blood glucose or poor blood glucose control in the last 6 months.
- •You are taking certain diabetes medications that are not allowed for study participation.
- •You have major problems with your heart, kidneys, liver, or you have a blood disorder.
- •You have had, or are now being treated for, certain types of cancer.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Phase 1
A study to compare an investigational ultra-rapid insulin, LY900014 with insulin lispro in children with type 1 diabetesDiabetes Mellitus, Type 1MedDRA version: 21.1Level: PTClassification code 10067584Term: Type 1 diabetes mellitusSystem Organ Class: 10027433 - Metabolism and nutrition disordersTherapeutic area: Diseases [C] - Hormonal diseases [C19]EUCTR2018-002371-18-ITELI LILLY & COMPANY, LILLY CORPORATE CENTER751
Active, not recruiting
Phase 1
A study to compare an investigational ultra-rapid insulin, LY900014 with insulin lispro in children with type 1 diabetesDiabetes Mellitus, Type 1MedDRA version: 20.0 Level: PT Classification code 10067584 Term: Type 1 diabetes mellitus System Organ Class: 10027433 - Metabolism and nutrition disordersTherapeutic area: Diseases [C] - Hormonal diseases [C19]EUCTR2018-002371-18-GBEli Lilly and Company708
Active, not recruiting
Phase 1
A study in people with type 1 diabetes to determine how well a meal-time insulin, LY900014, controls diabetes compared to Humalog (insulin lispro) when both are used along with a long-acting insulin.Type 1 DiabetesMedDRA version: 20.1Level: LLTClassification code 10020639Term: HyperglycemiaSystem Organ Class: 100000004861Therapeutic area: Diseases [C] - Hormonal diseases [C19]EUCTR2015-005356-99-PLEli Lilly and Company1,392
Active, not recruiting
Phase 1
A study in people with type 1 diabetes to determine how well a meal-time insulin, LY900014, controls diabetes compared to Humalog (insulin lispro) when both are used along with a long-acting insulin.Type 1 DiabetesMedDRA version: 19.1 Level: LLT Classification code 10020639 Term: Hyperglycemia System Organ Class: 100000004861Therapeutic area: Diseases [C] - Hormonal diseases [C19]EUCTR2015-005356-99-ESilly S.A.1,328
Active, not recruiting
Phase 1
A study to compare an investigational ultra-rapid insulin, LY900014 with insulin lispro in children with type 1 diabetesEUCTR2018-002371-18-DKEli Lilly and Company751